Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NCT04506242 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

74

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: SHR-1210
DRUG: Apatinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences